NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Fasikl, Inc.

Fasikl, Inc.

Private
Minneapolis, MinnesotaHealthcare & Life Scienceshttps://www.fasikl.com/

Last Round

Series B

Sep 10, 2025

Total Funding Raised

$59.8M

Company Overview

Fasikl, Inc. is a neuro-AI company that develops cloud-connected, AI-powered neuromodulation technologies and therapeutics for movement disorders.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Health IoT

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS

AI Layer

Application

Keywords

neuromodulationessential tremor treatmentmedical wearableclosed-loop neuromodulationnerve-computer interfaceBCIbrain-computer interfacemedical AIdigital therapeuticsDTxtranscutaneous neurostimulationmovement disorder therapyFDA-cleared devicehealth IoTbiohacking

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Fasikl, Inc. Comparables

Compare Fasikl, Inc. with similar companies based on industry and business-model similarity.

Fasikl, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Encora Therapeutics
87%
Allevion Therapeutics
85%
Cala Health
85%

Fasikl, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 10, 2025
Series A ExtensionSep 10, 2024
Series AMar 3, 2023
Early FundingNov 1, 2021

Key People

Founding team and executive leadership

Edward W. Keefer

Co-Founder and Chief Scientific Officer

Founding Team

Zhi Yang

CEO

Executive Team

Catherine Zhao

Chief Technology Officer

Executive Team

Fasikl, Inc. Investors

Notable investors and investment history

Fasikl, Inc. investors
InvestorRounds
iSeedSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    Grew 29% QoQ, from 14 to 18 employees.

  • Feb 15, 2026

    Grew 23% QoQ, from 13 to 16 employees.

Fasikl, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Fasikl, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Fasikl, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMinneapolis, Minnesota
Employee Range18
Year Founded2019
Last FundingSep 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.